enGene Therapeutics Inc. (ENGN)
$1.82-$0.08 (-4.45%) Today
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 9 | 448,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
28 Form 4 filings on record, the earliest from Oct 1, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Philip Astley-Sparke | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| Gerald A. Brunk | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| Richard M. Glickman | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| William Grossman - Officer | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| William Grossman - Officer | Grant or award | Stock Option (Right to Buy) | 200,000 | $0.00 | - | |
 Paul J. Hastings | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
 Michael Thomas Heffernan | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| Wouter Joustra | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| Lota S. Zoth | Grant or award | Stock Option (Right to Buy) | 31,000 | $0.00 | - | |
| Anthony Tzeyew Cheung - Officer | Grant or award | Stock Option (Right to Buy) | 195,000 | $0.00 | - | |
 Lee Giguere - Officer | Grant or award | Stock Option (Right to Buy) | 195,000 | $0.00 | - | |
 Alexander Julian Nichols - Officer | Grant or award | Stock Option (Right to Buy) | 195,000 | $0.00 | - | |
 D. Ryan Daws - Officer | Grant or award | Stock Option (Right to Buy) | 220,000 | $0.00 | - | |
| Ronald Harold Wilfred Cooper - Officer | Grant or award | Stock Option (Right to Buy) | 801,000 | $0.00 | - | |
| Joan Connolly - Officer | Grant or award | Stock Option (Right to Buy) | 195,000 | $0.00 | - | |
| Matthew Ross Boyd - Officer | Grant or award | Stock Option (Right to Buy) | 195,000 | $0.00 | - | |
| Jill Buck - Officer | Grant or award | Stock Option (Right to Buy) | 195,000 | $0.00 | - | |
| Hussein Sweiti - Officer | Grant or award | Stock Option (Right to Buy) | 600,000 | $0.00 | - | |
| Philip Astley-Sparke | Grant or award | Stock Option (Right to Buy) | 45,000 | $0.00 | - | |
| Michael Thomas Heffernan | Grant or award | Stock Option (Right to Buy) | 45,000 | $0.00 | - | |
| William Grossman | Grant or award | Stock Option (Right to Buy) | 45,000 | $0.00 | - | |
| Matthew Ross Boyd - Officer | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Jill Buck - Officer | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Lota S. Zoth | Grant or award | Stock Option (Right to Buy) | 22,500 | $0.00 | - | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 561,797 | $8.90 | $5.00M | |
| Joan Connolly - Officer | Grant or award | Stock Option (Right to Buy) | 210,000 | $0.00 | - | |
| Anthony Tzeyew Cheung - Officer | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 2,750 | $7.17 | $20K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 5,050 | $7.69 | $39K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 400 | $8.30 | $3K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 9,620 | $9.09 | $87K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 38,396 | $5.94 | $228K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 3,243 | $6.38 | $21K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 341,332 | $6.34 | $2.16M | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 35,279 | $6.44 | $227K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 10,153 | $6.37 | $65K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 5,769 | $6.48 | $37K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 5,997 | $6.54 | $39K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 11,844 | $6.55 | $78K | |
| Forbion Growth Opportunities Fund I Cooperatief U.A. | Open-market purchase | Common Shares | 800 | $6.60 | $5K | |
| Ronald Harold Wilfred Cooper - Officer | Open-market purchase | Common Shares | 10,000 | $5.70 | $57K |
enGene Therapeutics Inc. (ENGN) had 8 insider filings in the last 90 days, with the most recent on 2026-06-17. The full record for ENGN runs to 28 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ENGN were filed in the last 90 days. 15 purchases are on record for this company.
No insider sales of ENGN were filed in the last 90 days.
This page tracks ENGN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ENGN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
